| Original language | English (US) |
|---|---|
| Pages (from-to) | 1265-1274 |
| Number of pages | 10 |
| Journal | Drug Discovery Today |
| Volume | 26 |
| Issue number | 5 |
| Early online date | Jan 23 2021 |
| DOIs | |
| State | Published - May 2021 |
Keywords
- Animals
- Biomarkers/blood
- COVID-19/complications
- Ferritins/blood
- Heart Arrest/drug therapy
- Humans
- Hyperferritinemia/blood
- Iron Chelating Agents/therapeutic use
- Prognosis
- SARS-CoV-2/pathogenicity
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Drug Discovery Today, Vol. 26, No. 5, 05.2021, p. 1265-1274.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - SARS–CoV-2 Mediated Hyperferritinemia and Cardiac Arrest
T2 - Preliminary Insights
AU - VasanthiDharmalingam, Prakash
AU - Karuppagounder, Vengadeshprabhu
AU - Watanabe, Kenichi
AU - Karmouty‐Quintana, Harry
AU - Palaniyandi, Suresh S.
AU - Guha, Ashrith
AU - Thandavarayan, Rajarajan A.
N1 - Funding Information: This research was supported by grants from the American Heart Association ( 19TPA34880039 and 18IPA34170497 R.A.T) and the Roswell and Ann Vaughan Fund to A.G. We also thank those who edited the manuscript: Kelly A. Volcik, Department of Biochemistry and Molecular Biology & Divisions of Critical Care, Pulmonary and Sleep Medicine, Department of Internal Medicine, UTHealth–McGovern Medical School, Houston, TX 77030; Dr. Lakshmikanthan Paneerselvam Ph.D., SERB-NPDF (Govt. of India), Department of Human Genetics, National Institute of Mental Health and Neuroscience (NIMHANS), Bengaluru-560 029, Karnataka, India; and Dr.Raghunandhakumar Subramanian Ph.D, Professor, Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai-600 077, Tamil Nadu, India. Funding Information: This research was supported by grants from the American Heart Association (19TPA34880039and 18IPA34170497 R.A.T) and the Roswell and Ann Vaughan Fund to A.G. We also thank those who edited the manuscript: Kelly A. Volcik, Department of Biochemistry and Molecular Biology & Divisions of Critical Care, Pulmonary and Sleep Medicine, Department of Internal Medicine, UTHealth?McGovern Medical School, Houston, TX 77030; Dr. Lakshmikanthan Paneerselvam Ph.D. SERB-NPDF (Govt. of India), Department of Human Genetics, National Institute of Mental Health and Neuroscience (NIMHANS), Bengaluru-560 029, Karnataka, India; and Dr.Raghunandhakumar Subramanian Ph.D, Professor, Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai-600 077, Tamil Nadu, India.
PY - 2021/5
Y1 - 2021/5
KW - Animals
KW - Biomarkers/blood
KW - COVID-19/complications
KW - Ferritins/blood
KW - Heart Arrest/drug therapy
KW - Humans
KW - Hyperferritinemia/blood
KW - Iron Chelating Agents/therapeutic use
KW - Prognosis
KW - SARS-CoV-2/pathogenicity
UR - http://www.scopus.com/inward/record.url?scp=85100426483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100426483&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2021.01.014
DO - 10.1016/j.drudis.2021.01.014
M3 - Review article
C2 - 33493677
AN - SCOPUS:85100426483
SN - 1359-6446
VL - 26
SP - 1265
EP - 1274
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 5
ER -